December 18, 2025 01:46 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Indian Visa Application Centre in Dhaka shuts down early amid rising security concerns | Market update: Sensex tumbles 120 points, Nifty below 25,850 at closing bell | ‘Won’t apologise’: Prithviraj Chavan stands firm on controversial Operation Sindoor remark despite backlash | India summons Bangladesh High Commissioner after provocative 'seven sisters' remark | Amazon eyes $10 billion investment in OpenAI — a gamechanger for AI industry! | Goa nightclub fire horror: Luthra brothers brought back to India from Thailand, arrested | Messi chaos costs minister his job: Aroop Biswas resigns after Salt Lake Stadium fiasco | Bengal SIR draft list out: Around 58 lakh voters’ names dropped | Relief for Sonia, Rahul Gandhi as Delhi court refuses to act on ED chargesheet in National Herald case | Centre moves to replace MGNREGA with 'G Ram G', sets stage for winter session showdown
COVID-19 Vaccine
AdarPoonawala Twitter page

COVID-19 vaccine is safe, says Serum Institute of India on side effect claims  

| @indiablooms | Dec 01, 2020, at 10:13 pm

Pune-based  Serum Institute of India's (SII) said its 'COVISHIELD' vaccine is safe and immunogenic after a volunteer claimed that he suffered neurological and psychological side effects after taking a shot of the vaccine.

Rejecting all allegations, the institute said: "The incident with the Chennai volunteer though highly unfortunate was in no way induced by the vaccine and Serum Institute of India is sympathetic with the volunteer's medical condition. "

"However, we would like to clarify that all the requisite regulatory and ethical processes and guidelines were followed diligently and strictly," the institute said.

"The concerned authorities were informed and the Principal Investigator, DSMB and the Ethics Committee independently cleared and reckoned it as a non-related issue to the vaccine trial. Post which we submitted all the reports and data related to the incident to the DCGI. It is only after we cleared all the required processes that we continued with the trials," read the statement.

The Pune based institute said the vaccine will not be released for mass use unless it is proven immunogenic, and safe.  

"Taking into consideration the complexities and existing misnomers about vaccination and immunisation; the legal notice was sent therefore to safeguard the reputation of the company which is being unfairly maligned," it said.

The institute is conducting clinical trials of the  AstraZeneca-Oxford's Covid-19 vaccine in India.

The phase-3 clinical trial of the vaccine is currently being made across India.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.